A vaccine to protect against mycoplasma hyopneumoniae
AssigneeIntervet Inc.
InventorsJohanna Jacoba Elisabeth Bijlsma, Maarten Hendrik Witvliet
Life of this patent
Estimating the term…
Abstract
A vaccine comprising nanoparticles in association with a Mycoplasma hyopneumoniae bacterin, wherein the nanoparticles comprise a cationic polysaccharide and an anionic phospholipid.
Claims17
A vaccine comprising nanoparticles in association with a Mycoplasma hyopneumoniae bacterin, wherein the nanoparticles comprise a cationic polysaccharide and an anionic phospholipid.
(canceled)
The method according to claim 13, wherein the vaccine is administered systemically.
The method according to claim 13, wherein the vaccine is administered intradermally.
The method according to claim 13, wherein the vaccine is administered as a single dose.
The method according to claim 13, for use in the reduction of lung lesions due to the infection with Mycoplasma hyopneumoniae.
(canceled)
Dependencies are inferred from the claim text.